Volition’s initial Nu.Q™ products are focusing on colorectal cancer. Colorectal cancer is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and nearly 700,000 deaths worldwide.
- The Nu.Q™ Colorectal Cancer Screening Triage Test has demonstrated the potential to reduce colonoscopies by up to 25% while maintaining almost 97% detection of colorectal cancer. This product is CE Marked and is available for use in the EU Markets.
Products in development
- Interim results of a panel of 4 Nu.Q™ assays detected 81% of colorectal cancers at 78% specificity in a cohort of 4800 symptomatic patients.
- A panel of 4 normalised Nu.Q™ assays detected 67% of high risk adenomas at 80% specificity in a cohort of 530 symptomatic patients.
There is a clear medical need for a reliable, simple, and accurate diagnostic test for pancreatic cancer. Currently, emergency presentation is the most common route to diagnosis, and only 21% of patients survive for more than a year.
- A panel of 4 Nu.Q™ assays plus CA19-9 in a pilot study of 59 patients detected 92% of pancreatic cancers at 100% specificity
- Interim results of a panel of 2 Nu.Q™ assays plus CEA detected 95% of pancreatic cancers at 84% specificity.
Lung cancer is the most common cancer worldwide. Only 10% of lung cancer patients will survive for five years or more. Current screening methods for lung cancer are widely regarded as too inaccurate and expensive for widespread use.
- A panel of 4 Nu.Q™ assays in a pilot study of 73 patients detected 93% of lung cancers at 91% specificity.
Ongoing clinical trials
|Hvidore Hospital, University of Copenhagen||Colorectal cancer||Retrospective||4,800 sympomatic|
|Hvidore Hospital, University of Copenhagen||Colorectal cancer||Prospective||14,000 screening population|
|Hvidore Hospital, University of Copenhagen||Colorectal cancer and other||Prospective, longitudinal||30,000 screening population to provide 3 samples (90,000 samples total)|
|University of Bonn||27 most prevalent cancers||Prospective||4,700|
|German Cancer Research Center (DKFZ)||Pancreatic||Restrospective||750|